Augusto Vaglio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4222487/publications.pdf Version: 2024-02-01

	25034	30922
11,978	57	102
citations	h-index	g-index
212	212	9675
docs citations	times ranked	citing authors
	citations 212	11,978 57 citations h-index 212 212

#	Article	IF	CITATIONS
1	Response to: â€~Eosinophilic granulomatosis with polyangiitis can manifest lacrimal and salivary glands swelling by granulomatous inflammation: a potential mimicker of IgG4-related disease' by Akiyama <i>et al</i> . Annals of the Rheumatic Diseases, 2022, 81, e121-e121.	0.9	0
2	Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. Arthritis and Rheumatology, 2022, 74, 295-306.	5.6	78
3	Proteinuria selectivity index predicts response to rituximab in adults with minimal change disease and focal segmental glomerulosclerosis. Nephrology Dialysis Transplantation, 2022, 37, 789-791.	0.7	5
4	Type I interferon–related kidney disorders. Kidney International, 2022, 101, 1142-1159.	5.2	21
5	Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2022, 37, 2190-2200.	0.7	11
6	Effects of nucleases on cell-free extrachromosomal circular DNA. JCI Insight, 2022, 7, .	5.0	12
7	FC040: Kidney Transplantation in Childhood-Onset ANCA-Associated Vasculitis: Outcomes in a Multicentre Cohort. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
8	FC036: A Clinical Workflow for Selection of Patients and Cost-Efficient DiagnosisÂof Genetic Kidney Diseases. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
9	MO1057: Cost-Analysis of a Clinical Workflow for Diagnosis of Inherited Kidney Diseases. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
10	Gut Microbiota and Associated Mucosal Immune Response in Eosinophilic Granulomatosis with Polyangiitis (EGPA). Biomedicines, 2022, 10, 1227.	3.2	4
11	The Sound of Interconnectivity; The European Vasculitis Society 2022 Report. Kidney International Reports, 2022, 7, 1745-1757.	0.8	3
12	Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study. Annals of the Rheumatic Diseases, 2022, 81, 1769-1772.	0.9	9
13	A Report of 2 Cases of Kidney Involvement in ADA2 Deficiency: Different Disease Phenotypes and the Tissue Response to Type I Interferon. American Journal of Kidney Diseases, 2022, 80, 677-682.	1.9	1
14	Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Rheumatology, 2021, 60, 4355-4360.	1.9	21
15	Serum IgG2 antibody multi-composition in systemic lupus erythematosus and in lupus nephritis (Part) Tj ETQq1	1 0,78431 1.9	4 rgBT /Ove
16	Idiopathic retroperitoneal fibrosis: an update for nephrologists. Nephrology Dialysis Transplantation, 2021, 36, 1773-1781.	0.7	33
17	Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study. Arthritis and Rheumatology, 2021, 73, 498-503.	5.6	55
18	Slowly progressive anti-neutrophil cytoplasmic antibody-associated renal vasculitis: clinico-pathological characterization and outcome. CKJ: Clinical Kidney Journal, 2021, 14, 332-340.	2.9	17

#	Article	IF	CITATIONS
19	Isolated Aortitis and Periaortitis. Rare Diseases of the Immune System, 2021, , 199-209.	0.1	0
20	Into Clinical Practice: Diagnosis and Therapy of Retroperitoneal Fibrosis. Current Rheumatology Reports, 2021, 23, 18.	4.7	17
21	Cardiac involvement in eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss) Tj ETQq1 1 0.784 Medicine, 2021, 85, 68-79.	314 rgBT 2.2	/Overlock 10 14
22	Neutrophil Extracellular Traps in the Autoimmunity Context. Frontiers in Medicine, 2021, 8, 614829.	2.6	25
23	Microarray evaluation of allergen-specific IgE in eosinophilic granulomatosis with polyangiitis. Annals of the Rheumatic Diseases, 2021, 80, 1247-1248.	0.9	2
24	Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome). European Respiratory Journal, 2021, 57, 2004158.	6.7	19
25	Collapsing Glomerulopathy as a Complication of Type I Interferon–Mediated Glomerulopathy in a Patient With RNASEH2B-Related Aicardi-Goutières Syndrome. American Journal of Kidney Diseases, 2021, 78, 750-754.	1.9	11
26	FC 039RENAL OUTCOME AFTER RITUXIMAB IN ADULT-ONSET IGA VASCULITIS AND CRESCENTIC IGA NEPHROPATHY: A MULTICENTRE STUDY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	2
27	Prognostic Factors and Long-Term Outcome with ANCA-Associated Kidney Vasculitis in Childhood. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1043-1051.	4.5	19
28	IgG4-related disease: not just a matter of IgG4. Rheumatology, 2021, 60, iii35-iii38.	1.9	2
29	Editorial: Immune Monitoring Responses in Renal Autoimmune Diseases. Frontiers in Immunology, 2021, 12, 722791.	4.8	Ο
30	Occupational Exposures and Smoking in Eosinophilic Granulomatosis With Polyangiitis: A Case–Control Study. Arthritis and Rheumatology, 2021, 73, 1694-1702.	5.6	13
31	lgC4-related disease and Rosai-Dorfman-Destombes disease – Authors' reply. Lancet, The, 2021, 398, 1214-1215.	13.7	0
32	ANCA testing: where are we now?. Internal and Emergency Medicine, 2021, 16, 269-271.	2.0	1
33	Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis. Rheumatology, 2021, 60, 3176-3188.	1.9	9
34	Pediatric Erdheim-Chester Disease in the Molecular Era: A Multicenter Case Series. Blood, 2021, 138, 4194-4194.	1.4	1
35	Neutrophil Extracellular Traps Profiles in Patients with Incident Systemic Lupus Erythematosus and Lupus Nephritis. Journal of Rheumatology, 2020, 47, 377-386.	2.0	77
36	Manifestations of Skull Base IgG4â€Related Disease: A Multiâ€Institutional Study. Laryngoscope, 2020, 130, 2574-2580.	2.0	15

#	Article	IF	CITATIONS
37	Rituximab for chronic periaortitis without evidence of IgG4-related disease: a long-term follow-up study of 20 patients. Annals of the Rheumatic Diseases, 2020, 79, 433-434.	0.9	19
38	The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4â€Related Disease. Arthritis and Rheumatology, 2020, 72, 7-19.	5.6	292
39	Adult-onset IgA vasculitis (Henoch-Schönlein): Update on therapy. Presse Medicale, 2020, 49, 104035.	1.9	26
40	The rise of complement in ANCA-associated vasculitis: from marginal player to target of modern therapy. Clinical and Experimental Immunology, 2020, 202, 403-406.	2.6	17
41	P1805UNEXPECTD COMPLEMENT GENES ABNORALITIES IN CHILDREN WITH SECONDARY HEMOLITIC UREMIC SYNDROME. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
42	Multi-Autoantibody Signature and Clinical Outcome in Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1762-1776.	4.5	17
43	SARS-CoV-2 infection among patients with systemic autoimmune diseases. Autoimmunity Reviews, 2020, 19, 102575.	5.8	131
44	FCGR3B polymorphism predicts relapse risk in eosinophilic granulomatosis with polyangiitis. Rheumatology, 2020, 59, 3563-3566.	1.9	8
45	Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis. Annals of the Rheumatic Diseases, 2020, 79, 1077-1083.	0.9	49
46	Erdheim–Chester disease: a rapidly evolving disease model. Leukemia, 2020, 34, 2840-2857.	7.2	35
47	International Consensus on Antineutrophil Cytoplasm Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1360-1372.	5.6	36
48	Eosinophilic granulomatosis with polyangiitis: understanding the disease and its management. Rheumatology, 2020, 59, iii84-iii94.	1.9	53
49	IgG4-related disease: a clinical perspective. Rheumatology, 2020, 59, iii123-iii131.	1.9	84
50	Aortitis and periaortitis: The puzzling spectrum of inflammatory aortic diseases. Presse Medicale, 2020, 49, 104018.	1.9	21
51	Threatening drugâ€drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVIDâ€19). Transplant Infectious Disease, 2020, 22, e13286.	1.7	58
52	Erdheim-Chester disease: A challenging diagnosis for an effective therapy. Clinical Neurology and Neurosurgery, 2020, 194, 105841.	1.4	4
53	Reverse Phenotyping after Whole-Exome Sequencing in Steroid-Resistant Nephrotic Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 89-100.	4.5	60
54	Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood, 2020, 135, 1929-1945.	1.4	191

#	Article	IF	CITATIONS
55	Long-term follow-up of mTOR inhibition for Erdheim-Chester disease. Blood, 2020, 135, 1994-1997.	1.4	14
56	IgG4-related disease: a contemporary review. Turkish Journal of Medical Sciences, 2020, 50, 1616-1631.	0.9	24
57	Miscellaneous Organ Involvement in ANCA-Associated Vasculitis. Rare Diseases of the Immune System, 2020, , 269-292.	0.1	0
58	New therapeutics for ANCA-associated vasculitis: 10 years devoted to lessen toxicity. Clinical and Experimental Rheumatology, 2020, 38 Suppl 124, 18-22.	0.8	2
59	New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group. Internal and Emergency Medicine, 2019, 14, 1193-1197.	2.0	13
60	Podocytes and Proteinuria in ANCA-Associated Glomerulonephritis: A Case-Control Study. Frontiers in Immunology, 2019, 10, 1405.	4.8	9
61	FP165SLOWLY PROGRESSIVE ANCA-ASSOCIATED GLOMERULONEPHRITIS: A MULTICENTRE STUDY. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
62	Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nature Communications, 2019, 10, 5120.	12.8	160
63	Randomized trial of two after-dialysis gabapentin regimens for severe uremic pruritus in hemodialysis patients. Internal and Emergency Medicine, 2019, 14, 1341-1346.	2.0	7
64	Fibrocytes in Chronic Periaortitis: A Novel Mechanism Linking Inflammation and Fibrosis. Arthritis and Rheumatology, 2019, 71, 1913-1922.	5.6	17
65	Neutrophil Extracellular Traps protein composition is specific for patients with Lupus nephritis and includes methyl-oxidized αenolase (methionine sulfoxide 93). Scientific Reports, 2019, 9, 7934.	3.3	58
66	ANCA-Associated Vasculitis. Rare Diseases of the Immune System, 2019, , 111-128.	0.1	0
67	Clinical and Prognostic Significance of Serum IgG4 in Chronic Periaortitis. An Analysis of 113 Patients. Frontiers in Immunology, 2019, 10, 693.	4.8	22
68	Skull Base Manifestations of Erdheim-Chester Disease: A Case Series and Systematic Review. Neurosurgery, 2019, 85, E693-E701.	1.1	14
69	Stem-Cell-Derived Circulating Progenitors Dysfunction in Behçet's Syndrome Patients Correlates With Oxidative Stress. Frontiers in Immunology, 2019, 10, 2877.	4.8	11
70	Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Annals of the Rheumatic Diseases, 2019, 78, 399-405.	0.9	165
71	Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-211897.	0.9	32
72	Malignant Mönckeberg medial calcific sclerosis. Internal and Emergency Medicine, 2018, 13, 615-617.	2.0	8

#	Article	IF	CITATIONS
73	Adalimumabâ€Based Treatment Versus Diseaseâ€Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome. Arthritis and Rheumatology, 2018, 70, 1500-1507.	5.6	57
74	Changing patterns in clinical–histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Annals of the Rheumatic Diseases, 2018, 77, 1318-1325.	0.9	119
75	A misleading diagnosis of granulomatosis with polyangiitis disguising Whipple's disease. Rheumatology, 2018, 57, 1307-1309.	1.9	1
76	Brief Report: Rituximab for the Treatment of Adultâ€Onset IgA Vasculitis (Henochâ€Schönlein). Arthritis and Rheumatology, 2018, 70, 109-114.	5.6	71
77	[18 F]-Fluorodeoxyglucose Positron Emission Tomography and Response to Therapy in Idiopathic Retroperitoneal Fibrosis. European Urology, 2018, 73, 145-146.	1.9	16
78	FCGR2A single nucleotide polymorphism confers susceptibility to childhood-onset idiopathic nephrotic syndrome. Immunology Letters, 2018, 193, 11-13.	2.5	4
79	Chronic Periaortitis: an Update. Current Rheumatology Reports, 2018, 20, 80.	4.7	22
80	Low-dose tocilizumab for relapsing giant cell arteritis in the elderly, fragile patient: Beyond the GiACTA trial. Autoimmunity Reviews, 2018, 17, 1265-1267.	5.8	5
81	A large-scale genetic analysis reveals an autoimmune origin of idiopathic retroperitoneal fibrosis. Journal of Allergy and Clinical Immunology, 2018, 142, 1662-1665.	2.9	17
82	Histiocytoses. , 2018, , 379-390.		0
83	Annexin A1 and Autoimmunity: From Basic Science to Clinical Applications. International Journal of Molecular Sciences, 2018, 19, 1348.	4.1	58
84	Drug-induced lupus: Traditional and new concepts. Autoimmunity Reviews, 2018, 17, 912-918.	5.8	74
85	Hemoptysis in Behçet's syndrome: from bedside to bench?. Internal and Emergency Medicine, 2018, 13, 467-469.	2.0	6
86	Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E970-E979.	7.1	172
87	Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease. Internal and Emergency Medicine, 2017, 12, 287-299.	2.0	56
88	Histiocytoses: emerging neoplasia behind inflammation. Lancet Oncology, The, 2017, 18, e113-e125.	10.7	154
89	Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy. Scientific Reports, 2017, 7, 43953.	3.3	52
90	Complement blockade in ANCA-associated vasculitis: an index case, current concepts and future perspectives. Internal and Emergency Medicine, 2017, 12, 727-731.	2.0	29

#	Article	IF	CITATIONS
91	ANCA-associated vasculitis in childhood: recent advances. Italian Journal of Pediatrics, 2017, 43, 46.	2.6	71
92	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. American Journal of Human Genetics, 2017, 100, 64-74.	6.2	78
93	The European Vasculitis Society 2016 Meeting Report. Kidney International Reports, 2017, 2, 1018-1031.	0.8	21
94	Erdheim-Chester disease: the "targeted―revolution. Blood, 2017, 130, 1282-1284.	1.4	12
95	Antineutrophil cytoplasmic antibody-associated vasculitides and IgC4-related disease: A new overlap syndrome. Autoimmunity Reviews, 2017, 16, 1036-1043.	5.8	120
96	Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. RMD Open, 2017, 3, e000449.	3.8	23
97	Post-translational modified proteins are biomarkers of autoimmune-processes: NETosis and the inflammatory–autoimmunity connection. Clinica Chimica Acta, 2017, 464, 12-16.	1.1	16
98	Idiopathic Mediastinal Fibrosis: a Systemic Immune-Mediated Disorder. A Case Series and a Review of the Literature. Clinical Reviews in Allergy and Immunology, 2017, 52, 446-459.	6.5	36
99	Monogenic Autoinflammatory Diseases with Mendelian Inheritance: Genes, Mutations, and Genotype/Phenotype Correlations. Frontiers in Immunology, 2017, 8, 344.	4.8	37
100	Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial. PLoS ONE, 2017, 12, e0185880.	2.5	37
101	Retroperitoneal Fibrosis and the Spectrum of Chronic Periaortitis. Rare Diseases of the Immune System, 2017, , 101-115.	0.1	Ο
102	Erdheim-Chester Disease as a Mimic of IgG4-Related Disease. Medicine (United States), 2016, 95, e3625.	1.0	33
103	Cardiac involvement in Erdheim-Chester disease: an MRI study. Blood, 2016, 128, 2468-2471.	1.4	22
104	EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2016, 75, 1583-1594.	0.9	940
105	Kidney involvement in medium- and large-vessel vasculitis. Journal of Nephrology, 2016, 29, 495-505.	2.0	18
106	Idiopathic Retroperitoneal Fibrosis. Journal of the American Society of Nephrology: JASN, 2016, 27, 1880-1889.	6.1	123
107	FcÎ ³ -receptor 3B (FCGR3B) copy number variations in patients with eosinophilic granulomatosis with polyangiitis. Journal of Allergy and Clinical Immunology, 2016, 137, 1597-1599.e8.	2.9	18
108	Immunoglobulin G4-related disease: some missing pieces in a still unsolved complex puzzle. Cardiovascular Pathology, 2016, 25, 90-92.	1.6	10

#	Article	IF	CITATIONS
109	Neutrophil Activation Promotes Fibrinogen Oxidation and Thrombus Formation in Behçet Disease. Circulation, 2016, 133, 302-311.	1.6	125
110	Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial. Blood, 2015, 126, 1163-1171.	1.4	69
111	The evolving paradigm of cancer risk related to cyclophosphamide therapy in granulomatosis with polyangiitis: Table 1. Rheumatology, 2015, 54, 1339-1341.	1.9	11
112	Idiopathic and secondary forms of retroperitoneal fibrosis: A diagnostic approach. Revue De Medecine Interne, 2015, 36, 15-21.	1.0	71
113	Multifocal phaeohyphomycosis caused by <i><scp>E</scp>xophiala xenobiotica</i> in a kidney transplant recipient. Transplant Infectious Disease, 2015, 17, 297-302.	1.7	14
114	Chronic periaortitis with thoracic aorta and epiaortic artery involvement: a systemic large vessel vasculitis?. Rheumatology, 2015, 54, 2004-2009.	1.9	32
115	First report of <i>FIP1L1-PDGFRα</i> -positive eosinophilic granulomatosis with polyangiitis : Fig. 1. Rheumatology, 2015, 54, 1751-1753.	1.9	13
116	Thrombosis in vasculitis: from pathogenesis to treatment. Thrombosis Journal, 2015, 13, 15.	2.1	112
117	Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference. Autoimmunity Reviews, 2015, 14, 692-702.	5.8	63
118	Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. European Journal of Internal Medicine, 2015, 26, 545-553.	2.2	371
119	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. American Journal of Human Genetics, 2015, 96, 565-580.	6.2	144
120	Association of Serum C3 Concentration and Histologic Signs of Thrombotic Microangiopathy with Outcomes among Patients with ANCA-Associated Renal Vasculitis. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 2143-2151.	4.5	67
121	Association between idiopathic retroperitoneal fibrosis and autoimmune thyroiditis: A case–control study. Autoimmunity Reviews, 2015, 14, 16-22.	5.8	36
122	Asbestos and Smoking as Risk Factors for Idiopathic Retroperitoneal Fibrosis. Annals of Internal Medicine, 2014, 161, 181.	3.9	64
123	Genetic aspects of anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrology Dialysis Transplantation, 2014, 30 Suppl 1, i37-45.	0.7	22
124	The Kidney Donor Profile Index (KDPI) of Marginal Donors Allocated by Standardized Pretransplant Donor Biopsy Assessment: Distribution and Association With Graft Outcomes. American Journal of Transplantation, 2014, 14, 2515-2525.	4.7	105
125	Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon-α (IFN-α) in Operable Renal Cell Carcinoma (RCC). Journal of Immunotherapy, 2014, 37, 440-447.	2.4	61
126	Eosinophilic granulomatosis with polyangiitis (Churg–Strauss). Current Opinion in Rheumatology, 2014, 26, 16-23.	4.3	110

#	Article	IF	CITATIONS
127	Treatment of idiopathic retroperitoneal fibrosis. Expert Opinion on Orphan Drugs, 2014, 2, 769-777.	0.8	1
128	Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood, 2014, 124, 483-492.	1.4	462
129	Impact of Posttransplant Lymphoproliferative Disorders on Kidney Graft Survival. Transplantation, 2014, 98, e21-e25.	1.0	3
130	A Candidate Gene Approach Identifies an IL33 Genetic Variant as a Novel Genetic Risk Factor for GCA. PLoS ONE, 2014, 9, e113476.	2.5	17
131	Polyreactive Antibodies Developing Amidst Humoral Rejection of Human Kidney Grafts Bind Apoptotic Cells and Activate Complement. American Journal of Transplantation, 2013, 13, 2590-2600.	4.7	52
132	Brief Report: Interleukinâ€6 as an Inflammatory Mediator and Target of Therapy in Chronic Periaortitis. Arthritis and Rheumatism, 2013, 65, 2469-2475.	6.7	51
133	Eosinophilic granulomatosis with polyangiitis (<scp>C</scp> hurg– <scp>S</scp> trauss): state of the art. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 261-273.	5.7	214
134	Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor–dependent idiopathic nephrotic syndrome. Kidney International, 2013, 84, 1025-1033.	5.2	109
135	Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature. Nephrology Dialysis Transplantation, 2013, 28, 2246-2259.	0.7	59
136	Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis. Annals of the Rheumatic Diseases, 2013, 72, 1584-1586.	0.9	56
137	Comparison of PR3-ANCA specific assay performance for the diagnosis of granulomatosis with polyangiitis (Wegener's). Clinical Chemistry and Laboratory Medicine, 2013, 51, 2141-2149.	2.3	11
138	Trends in Immune Cell Function Assay and Donor-Specific HLA Antibodies in Kidney Transplantation: A 3-Year Prospective Study. American Journal of Transplantation, 2013, 13, 3215-3222.	4.7	17
139	TLR-4 and VEGF Polymorphisms in Chronic Periaortitis. PLoS ONE, 2013, 8, e62330.	2.5	8
140	Rituximab therapy for chronic periaortitis. Annals of the Rheumatic Diseases, 2012, 71, 1262-1264.	0.9	53
141	lgG4 immune response in Churg–Strauss syndrome. Annals of the Rheumatic Diseases, 2012, 71, 390-393.	0.9	171
142	Churg–Strauss syndrome. Current Opinion in Rheumatology, 2012, 24, 24-30.	4.3	83
143	PTPN22 R620W polymorphism in the ANCA-associated vasculitides. Rheumatology, 2012, 51, 805-812.	1.9	60
144	Eotaxin/CCL11 in idiopathic retroperitoneal fibrosis. Nephrology Dialysis Transplantation, 2012, 27, 3875-3884.	0.7	29

#	Article	IF	CITATIONS
145	Membrano-proliferative glomerulonephritis, atypical hemolytic uremic syndrome, and a new complement factor H mutation: report of a case. Pediatric Nephrology, 2012, 27, 1995-1999.	1.7	15
146	Retroperitoneal fibrosis. Best Practice and Research in Clinical Rheumatology, 2012, 26, 439-448.	3.3	51
147	Genetically Distinct Subsets within ANCA-Associated Vasculitis. New England Journal of Medicine, 2012, 367, 214-223.	27.0	820
148	Differential Structural Remodeling of the Leftâ€Atrial Posterior Wall in Patients Affected by Mitral Regurgitation with or Without Persistent Atrial Fibrillation: A Morphological and Molecular Study. Journal of Cardiovascular Electrophysiology, 2012, 23, 271-279.	1.7	63
149	Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. Annals of the Rheumatic Diseases, 2011, 70, 80-85.	0.9	47
150	Chronic Periaortitis (CP). Medical Radiology, 2011, , 175-185.	0.1	0
151	Candida sake as the causative agent of spondylodiscitis in a hemodialysis patient. Spine Journal, 2011, 11, e12-e16.	1.3	9
152	Subclinical Interstitial Lung Abnormalities in Stable Renal Allograft Recipients in the Era of Modern Immunosuppression. Transplantation Proceedings, 2011, 43, 2617-2623.	0.6	23
153	Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet, The, 2011, 378, 338-346.	13.7	189
154	Chronic periaortitis: a large-vessel vasculitis?. Current Opinion in Rheumatology, 2011, 23, 1-6.	4.3	73
155	Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study. Rheumatology, 2011, 50, 1823-1827.	1.9	78
156	CC chemokine receptor 5 polymorphism in chronic periaortitis. Rheumatology, 2011, 50, 1025-1032.	1.9	25
157	A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. Rheumatology, 2011, 50, 899-905.	1.9	89
158	Role of 18F-fluorodeoxyglucose positron emission tomography in the workup of retroperitoneal fibrosis. Clinical and Experimental Rheumatology, 2011, 29, S72-8.	0.8	17
159	Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-α for metastatic renal cell cancer. Cancer Immunology, Immunotherapy, 2010, 59, 553-561.	4.2	22
160	EBV-Associated Leukoencephalopathy with Late Onset of Central Nervous System Lymphoma in a Kidney Transplant Recipient. American Journal of Transplantation, 2010, 10, 947-951.	4.7	13
161	Increased viral load after intravenous immunoglobulin therapy for BK virus-associated nephropathy. Transplant Infectious Disease, 2010, 12, 470-472.	1.7	16
162	Increased fetuin-A levels following treatment with a vitamin D analog. Kidney International, 2010, 78, 1187.	5.2	12

#	Article	IF	CITATIONS
163	Management of Hepatitis C Virus-related Mixed Cryoglobulinemia. American Journal of Medicine, 2010, 123, 400-408.	1.5	57
164	Chronic periaortitis associated with membranous nephropathy: clues to common pathogenetic mechanisms. Clinical Nephrology, 2010, 74, 485-490.	0.7	27
165	Churg–Strauss syndrome. Kidney International, 2009, 76, 1006-1011.	5.2	39
166	Chronically Administered Immunotherapy with Low-Dose IL-2 and IFN-α in Metastatic Renal Cell Carcinoma: A Feasible Option for Patients with a Good Prognostic Profile. Oncology, 2009, 76, 69-76.	1.9	10
167	Retroperitoneal fibrosis associated with psoriasis: a case series. Scandinavian Journal of Rheumatology, 2009, 38, 68-69.	1.1	15
168	Chronic periaortitis: a fibro-inflammatory disorder. Best Practice and Research in Clinical Rheumatology, 2009, 23, 339-353.	3.3	79
169	Peri-renal Collateral Circles. Urology, 2009, 74, 292-293.	1.0	7
170	Uraemic Pruritus. Drugs, 2009, 69, 251-263.	10.9	92
171	Retroperitoneal Fibrosis. Medicine (United States), 2009, 88, 208-210.	1.0	33
172	TLR-mediated induction of negative regulatory ligands on dendritic cells. Journal of Molecular Medicine, 2008, 86, 443-455.	3.9	30
173	Eprodisate in amyloid A amyloidosis: a novel therapeutic approach?. Expert Opinion on Pharmacotherapy, 2008, 9, 2175-2180.	1.8	16
174	Chronic Periaortitis. Circulation, 2008, 118, 1214-1216.	1.6	14
175	Pericarditis Heralding Erdheim-Chester Disease. Circulation, 2008, 118, e511-2.	1.6	22
176	Gabapentin as a therapeutic option in uremic pruritus. Kidney International, 2008, 73, 512.	5.2	11
177	Meningeal involvement in apparently ANCA-negative Wegener's granulomatosis: a role for PR3 capture-ELISA?. Rheumatology, 2007, 46, 1375-1376.	1.9	8
178	Pure red cell aplasia followed by disseminated intravascular coagulation in a haemodialysis patient receiving erythropoietin-Â. Nephrology Dialysis Transplantation, 2007, 22, 1465-1467.	0.7	5
179	Eprodisate in AA Amyloidosis. New England Journal of Medicine, 2007, 357, 1153-1154.	27.0	3
180	Gabapentin use in chronic uraemic itch is in line with emerging pathogenetic hypothesis. Nephrology Dialysis Transplantation, 2007, 22, 3669-3670.	0.7	4

#	Article	IF	CITATIONS
181	Peripheral inflammatory arthritis in patients with chronic periaortitis: report of five cases and review of the literature. Rheumatology, 2007, 47, 315-318.	1.9	23
182	Retroperitoneal Fibrosis: Evolving Concepts. Rheumatic Disease Clinics of North America, 2007, 33, 803-817.	1.9	74
183	Idiopathic retroperitoneal fibrosis: Clinicopathologic features and differential diagnosis. Kidney International, 2007, 72, 742-753.	5.2	164
184	HLA–DRB4 as a genetic risk factor for Churg‣trauss syndrome. Arthritis and Rheumatism, 2007, 56, 3159-3166.	6.7	168
185	Retroperitoneal fibrosis. Lancet, The, 2006, 367, 241-251.	13.7	612
186	Tamoxifen Therapy for Retroperitoneal Fibrosis. Annals of Internal Medicine, 2006, 144, 619.	3.9	4
187	167 REGULATION OF INNATE AND ADAPTIVE IMMUNE RESPONSES BY HUMAN ARTERIES Journal of Investigative Medicine, 2006, 54, S285.5-S285.	1.6	0
188	254 VASCULAR DENDRITIC CELLS IN GIANT CELL ARTERITIS: TRIGGERING OF VASCULAR INFLAMMATION BY TOLL-LIKE RECEPTOR LIGANDS Journal of Investigative Medicine, 2006, 54, S301.4-S301.	1.6	0
189	Calciphylaxis: evolving concepts. Internal and Emergency Medicine, 2006, 1, 320-322.	2.0	2
190	Autoimmune aspects of chronic periaortitis. Autoimmunity Reviews, 2006, 5, 458-464.	5.8	97
191	Chronic periaortitis and HLA–DRB1*03: Another clue to an autoimmune origin. Arthritis and Rheumatism, 2006, 55, 126-130.	6.7	102
192	Ear, nose and throat manifestations of Churg-Strauss syndrome. Acta Oto-Laryngologica, 2006, 126, 503-509.	0.9	123
193	Outcome and prognostic factors during the course of primary small-vessel vasculitides. Journal of Rheumatology, 2006, 33, 1299-306.	2.0	44
194	Chronic periaortitis: a spectrum of diseases. Current Opinion in Rheumatology, 2005, 17, 34-40.	4.3	145
195	18F-fluorodeoxyglucose positron emission tomography in the diagnosis and followup of idiopathic retroperitoneal fibrosis. Arthritis and Rheumatism, 2005, 53, 122-125.	6.7	65
196	Positron emission tomography (PET): Evaluation of chronic periaortitis. Arthritis and Rheumatism, 2005, 53, 298-303.	6.7	128
197	Tuberculosis as a Trigger of Retroperitoneal Fibrosis. Clinical Infectious Diseases, 2005, 41, e72-e75.	5.8	32
198	Gabapentin for uraemic pruritus. Nephrology Dialysis Transplantation, 2005, 20, 1278-1279.	0.7	15

#	Article	IF	CITATIONS
199	Reply to the letter of Dr A. Janin. Human Pathology, 2005, 36, 593.	2.0	0
200	Gabapentin in the treatment of uremic itch: an index case and a pilot evaluation. Journal of Nephrology, 2005, 18, 86-91.	2.0	59
201	Post-treatment residual tissue in idiopathic retroperitoneal fibrosis: active residual disease or silent "scar" ? A study using 18F-fluorodeoxyglucose positron emission tomography. Clinical and Experimental Rheumatology, 2005, 23, 231-4.	0.8	46
202	Large Bowel Obstruction Heralding Churg-Strauss Syndrome. American Journal of Gastroenterology, 2004, 99, 562-563.	0.4	16
203	Eosinophilic myocarditis in a patient with idiopathic hypereosinophilic syndrome: Insights into mechanisms of myocardial cell death. Human Pathology, 2004, 35, 1160-1163.	2.0	70
204	"Late" regressions of metastases from renal cancer after a period of disease progression continuing the same intermittent low dose immunotherapy regimen. Acta Biomedica, 2004, 75, 126-30.	0.3	2
205	Prognostic Significance of Albuminuria in Patients With Renal Cell Cancer. Journal of Urology, 2003, 170, 1135-1137.	0.4	21
206	Evidence of autoimmunity in chronic periaortitis: a prospective study. American Journal of Medicine, 2003, 114, 454-462.	1.5	191
207	ANCA-positive periaortic vasculitis: does it fall within the spectrum of vasculitis?. Journal of Internal Medicine, 2002, 251, 268-271.	6.0	49
208	Long-term immunotherapy with low-dose interleukin-2 and interferon-? in the treatment of patients with advanced renal cell carcinoma. Cancer, 2001, 92, 2286-2296.	4.1	53